CD83 and graft versus host disease: The CD83-targeted chimeric antigen receptor (CAR) T cell targeted therapy was proposed based on the report by Shrestha and colleagues that CD83 was a novel target against graft-versus-host disease in AML patients undergoing bone marrow hematopoietic stem cell transplantation [31].